Explore 10 essential options strategies every investor should know, from basic calls and puts to advanced spreads, risks, rewards, and real-world use cases explained.

Retirement planning centers around two key goals: generating reliable income and managing investment risks. Options offer retirees a way to achieve both, balancing steady income and downside ...

Like any plugged-in entrepreneur, an RIA owner needs a firm grasp of the financing options available for underwriting growth. However, the advantages and drawbacks of these methods can be hard to see.

In the financial world, opportunities oftentimes lie where risk and reward intersect. Options trading is one such intersection, offering diverse strategies to leverage the market’s volatility.

The jade lizard options strategy, invented by the original Lizard Trader, is a risk-defined, bull put credit spread. Using a spread of options with different strike prices but the same expiration date ...

YieldMax MSFT Option Income Strategy ETF offers high income through option premiums, but caps upside and exposes investors to single stock risk. MSFO's synthetic covered call strategy mimics MSFT's ...

French video game publisher Ubisoft said Thursday it's appointing advisors to review and pursue strategic options after a report last year suggested that its majority backers were considering a buyout ...

Investors can generate income from their portfolios in multiple ways, including selling covered calls. Managing an options portfolio can be complex. The Amplify CWP Enhanced Dividend Income ETF offers ...

R3 started out as a consortium and grew fast. Now it is reportedly waiting to see where fate takes it next. Enterprise blockchain services provider R3 is looking for strategic options. It has been ...

As Hoboken-based Hain Celestial continues a review of its core assets, it may look to sell off its personal care business. According to Hain Chief Executive Officer and President Wendy Davidson, the ...

Ubisoft, the French gaming company behind “Assassin’s Creed,” acknowledged a recent report that it may be sold off, saying it “regularly reviews all its strategic options” in a statement Monday. The ...

Relmada Therapeutics (NASDAQ:RLMD) shares finished Monday’s session 5% higher after the company reported it would no longer pursue two Phase 3 studies for its drug REL-1017 and was exploring strategic ...